The Clinical Trials of Immunotech Laboratories IPF Immunotherapy Treatment

Written by on February 28, 2013 in Features - No comments

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases.

Harry Zhabilov, president and chief science officer at Immunotech Laboratories with a PhD. in biochemistry, disclosed that they are currently performing clinical trials in Mexico on a unique immunotherapy treatment involving an inactivated pepsin fraction (IPF), a sterile biological product that helps fight malignant cells for cancer and treats HIV infection very effectively.

The Nabors Group and Immunotech Laboratories are currently in phases of IND and clinical trials.

Immunotherapy, also referred to as biologic therapy or biotherapy, is a treatment that uses certain parts of the immune system to fight diseases. This can be achieved in a couple of ways:

  • Stimulating the patient’s immune system to work harder or smarter to attack cancer cells
  • Giving the patient immune system components, such as man-made immune system proteins (an example being IPF, in the case of this trial)

The focus in this trial is with salvage patients and Immunotech has had a good success rate with immunotherapy in treating HIV and cancer (prostate, ovarian and pancreatic cancer) with little or no side effects from the treatment. Their concentration on salvage patients is an area big pharma is not interested in. Salvage therapy is a form of treatment given after an ailment does not respond to standard treatment, with the most common ailments being HIV and various tumors. Antiretroviral drugs (ARVs) are given to slow down the HIV reproduction or tumor growth, which in turn increases quality of life and survival.If the patient’s viral load starts to increase instead of staying very low, it almost always means the virus has developed a resistance to the ARVs. As more and more mutations develop, it becomes harder to select an ARV that will contain it. Salvage therapy is the attempt to contain it and can be used when at least one regimen containing protease inhibitors has failed in a patient.

With regard to HIV, the IPF based vaccine has been studied as a salvage therapy on stage CDC-3 AIDS patients using a mono approach. The results of four non-US experimental trials on 200 patients show the action and effectiveness of the vaccine. Immunological results are;

  1. Increase in percentages and numbers of CD8 and CCR5 positive cells in the treated patients.
  2. Significant Iincrease in CD8+, CD38+ cells in the treated patients.
  3. Significant increase in both CD4+ iNFg, secreting cells in the treated patients.


The major goal of immune therapy with cancer patients is to harness a patient’s immune system against tumor cells.  The technology developed over a decade by Dr. Zhabilov, involves treatment to increase the immunogenicity of cancer cells. This immunogenicity leads to an induction of anticancer immune response, specifically cancer T cells responses. IPF increases levels of interference (IFNs). Clear demonstrations are available of increased immunogenicity of treated melanoma cells.  Immunogenicity of the vaccine is further enhanced through the inclusion of proprietary adjuvant IL2. This adjuvant act to protect the immune cells activated in response to the vaccine.  This protection increases survival and prolongs the post vaccine immune response.

Currently Immunotech Laboratories, Dr. Zhabilov shared, is conducting pilot studies in Mexico and is in negotiations with two of the largest Bulgarian hospitals for the start of clinical trials for their patented IPF-ITV and IPF-ITV Phases on 50 advanced stage patients. Each country has different requirements for clinical trials. For this trial Bulgaria requires not less than 150 patients, while the United States requires 1000. Bulgaria has been selected for the “country of origin” for this clinical trial through their associate company, Immunotech BG.

Dr. Zhabilov stated, “The clinical trials in Bulgaria are scheduled to begin in March 2013 and will end in August 2013, which will give us the necessary results to receive approval for increased application for mass distribution for our IPF medicine.”

For more information visit or

This article contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

By Thomas Hibbard, Creative Director, Med Monthly

Leave a Comment

Please type the characters of this captcha image in the input box

Please type the characters of this captcha image in the input box